The University of Chicago Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Justin Kline and Michael Bishop.
Justin Kline
Connection Strength
2.253
Michael Bishop
  1. Update on checkpoint blockade therapy for lymphoma. J Immunother Cancer. 2015; 3:33.
    View in: PubMed
    Score: 0.508
  2. Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459.
    View in: PubMed
    Score: 0.191
  3. Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. Leuk Lymphoma. 2021 06; 62(6):1497-1501.
    View in: PubMed
    Score: 0.186
  4. Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials. Transplant Cell Ther. 2021 02; 27(2):105-107.
    View in: PubMed
    Score: 0.185
  5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer. 2020 12; 8(2).
    View in: PubMed
    Score: 0.184
  6. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2017; 5:11.
    View in: PubMed
    Score: 0.142
  7. Emerging role of checkpoint blockade therapy in lymphoma. Ther Adv Hematol. 2017 Feb; 8(2):81-90.
    View in: PubMed
    Score: 0.141
  8. FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients. Ann Transl Med. 2024 Jun 10; 12(3):49.
    View in: PubMed
    Score: 0.058
  9. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
    View in: PubMed
    Score: 0.056
  10. A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
    View in: PubMed
    Score: 0.054
  11. Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents. Matter. 2021 Dec 01; 4(12):3917-3940.
    View in: PubMed
    Score: 0.049
  12. Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591.
    View in: PubMed
    Score: 0.046
  13. Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1025-1027.
    View in: PubMed
    Score: 0.043
  14. Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplant. 2020 06; 55(6):1161-1168.
    View in: PubMed
    Score: 0.043
  15. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498.
    View in: PubMed
    Score: 0.043
  16. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
    View in: PubMed
    Score: 0.041
  17. Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Exp Hematol Oncol. 2019; 8:1.
    View in: PubMed
    Score: 0.040
  18. Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019 03; 60(3):629-638.
    View in: PubMed
    Score: 0.039
  19. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
    View in: PubMed
    Score: 0.038
  20. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365.
    View in: PubMed
    Score: 0.037
  21. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90.
    View in: PubMed
    Score: 0.035
  22. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072.
    View in: PubMed
    Score: 0.033
  23. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leuk Lymphoma. 2016 08; 57(8):1807-13.
    View in: PubMed
    Score: 0.033
  24. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.